頭頸部がん治療薬の世界市場レポート 2025年

頭頸部がん治療薬市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR10.6％で28億5,000万米ドルに成長します。予測期間の成長は、免疫療法の進歩、精密医療へのアプローチ、認知度向上と早期診断キャンペーン、世界の高齢化に起因しています。予測期間における主な動向としては、標的療法の役割拡大、低侵襲手術手技の採用、緩和ケアの統合、新規バイオマーカーの探索、患者中心のケアモデルなどが挙げられます。

頭頸部がんの有病率の上昇は、頭頸部がん治療薬市場の成長を牽引すると予測されます。頭頸部がんは、頭頸部組織における細胞の制御不能な増殖を伴う疾患であり、がん細胞の変異や異常に対処するための診断・治療オプションの改善が必要です。2023年、Cancer Research UKの予測によると、英国では2023年から2025年にかけて頭頸部がんの発生率が3％増加します。さらに、頭頸部がんに起因する死亡者数は同期間に12％増加すると予想されており、効果的な治療介入の必要性が高まっていることが強調されています。

タバコとアルコールの高水準の消費は、頭頸部がん治療薬市場の拡大に寄与すると予想されます。タバコ製品やアルコール飲料の習慣的な使用により、口、喉、喉頭などの粘膜が発がん性物質にさらされ、頭頸部がんのリスクが高まる。2023年8月、米国家庭医学会は、電子タバコの販売本数が2020年1月から2022年12月までに46％以上増加し、大幅に急増したと報告しました。この増加は、米国成人の電子タバコ使用率が2020年の3.7%から2022年には6%に上昇したことと合わせて、頭頸部がんの有病率に対するタバコの大量消費の影響を強調し、それによって治療ソリューションの需要を促進しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界頭頸部がん治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の頭頸部がん治療薬市場：成長率分析
• 世界の頭頸部がん治療薬市場の実績：規模と成長, 2019-2024
• 世界の頭頸部がん治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界頭頸部がん治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の頭頸部がん治療薬市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• プログラム細胞死（PD）阻害剤
• 微小管阻害剤
• 上皮成長因子受容体（EGFR）阻害剤
• 世界の頭頸部がん治療薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 注射可能
• オーラル
• 世界の頭頸部がん治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 小売および専門薬局
• 病院薬局
• オンライン薬局
• 世界の頭頸部がん治療薬市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 手術
• 放射線治療
• 化学療法
• 免疫療法
• その他の用途
• 世界の頭頸部がん治療薬市場プログラム細胞死（PD）阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• PD-1阻害剤
• PD-L1阻害剤
• 世界の頭頸部がん治療薬市場、微小管阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• タキサン
• ビンカアルカロイド
• 世界の頭頸部がん治療薬市場上皮成長因子受容体（EGFR）阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• モノクローナル抗体
• チロシンキナーゼ阻害剤

第7章 地域別・国別分析

• 世界の頭頸部がん治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の頭頸部がん治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 頭頸部がん治療薬市場：競合情勢
• 頭頸部がん治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• Sanofi Aventis LLC
• Bristol-Myers-Squibb Company
• AstraZeneca PLC
• GlaxoSmithKline plc.
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Amgen Inc.
• Boehringer Ingelheim International GmbH
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc.
• Daiichi Sankyo Company Limited
• Eisai Co. Ltd.
• Sun Pharmaceutical Industries Ltd.
• Incyte Corporation

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 頭頸部がん治療薬市場2029：新たな機会を提供する国
• 頭頸部がん治療薬市場2029：新たな機会を提供するセグメント
• 頭頸部がん治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Head and neck cancer therapeutics encompass a range of treatments designed to address and manage cancers affecting these areas. Precision therapies such as intensity-modulated proton therapy are beneficial in this domain. This includes an array of treatments such as surgery, radiation therapy, chemotherapy, specialized medications, and immunotherapy to combat these specific cancers.

The primary types of head and neck cancer therapeutics are programmed cell death (PD) inhibitors, microtubule inhibitors, and epidermal growth factor receptor (EGFR) inhibitors. PD inhibitors, such as programmed cell death protein 1 (PD-1) inhibitors, function by obstructing interactions between PD-1 and its ligands, PD-L1 and PD-L2, present in certain cancer cells. These medications are administered through injectable or oral routes and are available through multiple distribution channels such as retail and specialty pharmacies, hospital pharmacies, and online pharmacies. They find application in surgery, radiation therapy, chemotherapy, immunotherapy, and other treatment modalities.

The head and neck cancer therapeutics research report is one of a series of new reports from The Business Research Company that provides head and neck cancer therapeutics market statistics, including the head and neck cancer therapeutics industry's global market size, regional shares, competitors with head and neck cancer therapeutics market share, detailed head and neck cancer therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the head and neck cancer therapeutics industry. This head and neck cancer therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The head and neck cancer therapeutics market size has grown rapidly in recent years. It will grow from $1.71 billion in 2024 to $1.9 billion in 2025 at a compound annual growth rate (CAGR) of 11.3%. The growth in the historic period can be attributed to tobacco and alcohol consumption, human papillomavirus (HPV) infections, environmental exposures, and treatment modalities evolution

The head and neck cancer therapeutics market size is expected to see rapid growth in the next few years. It will grow to $2.85 billion in 2029 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to immunotherapy advances, precision medicine approaches, awareness and early diagnosis campaigns, global aging population. Major trends in the forecast period include the expanding role of targeted therapies, adoption of minimally invasive surgical techniques, integration of palliative care, exploration of novel biomarkers, and patient-centric care models.

The rising prevalence of head and neck cancer is anticipated to drive the growth of the head and neck cancer therapeutics market. This medical condition involves the uncontrolled growth of cells in the tissues of the head and neck region, necessitating improved diagnostic and treatment options to address mutations and abnormalities in cancer cells. In 2023, projections from Cancer Research UK indicate a 3% increase in the incidence of head and neck cancer in the UK between 2023 and 2025. Additionally, deaths attributed to head and neck cancers are expected to rise by 12% during the same period, underscoring the growing need for effective therapeutic interventions.

The consumption of tobacco and alcohol at high levels is expected to contribute to the expansion of the head and neck cancer therapeutics market. Habitual use of tobacco products and alcoholic beverages exposes the lining of the mouth, throat, larynx, and other areas to carcinogenic substances, leading to an increased risk of head and neck cancer. Notably, in August 2023, the American Academy of Family Physicians reported a significant surge in e-cigarette unit sales, rising by over 46% from January 2020 to December 2022. This increase, along with a rise in e-cigarette use among U.S. adults to 6% in 2022 from 3.7% in 2020, emphasizes the impact of high tobacco consumption on the prevalence of head and neck cancer, thereby driving the demand for therapeutic solutions.

Leading companies in the head and neck cancer therapeutics market are focused on introducing novel drug treatments to address the needs of patients with head and neck cancer. Drug treatment involves the use of pharmaceutical substances to manage or alleviate medical conditions, and in October 2023, Coherus BioSciences Inc., a U.S.-based biopharmaceutical company, achieved FDA approval for its latest drug, 'Loqtorzi' (toripalimab-tpzi). The approval allows for the use of the drug in combination with cisplatin and gemcitabine as the initial treatment for adults diagnosed with metastatic or recurrent, locally advanced nasopharyngeal carcinoma. The clinical trial demonstrated favorable results, with adverse reactions occurring in fewer than 20% of patients, whether used as a first-line option or as a single-agent therapy.

Major players in the head and neck cancer therapeutics market are also dedicated to developing innovative solutions, such as AI-enabled MR (Magnetic Resonance) imaging. This approach involves incorporating artificial intelligence (AI) technology into the MR process, optimizing various aspects from image acquisition to interpretation. In October 2022, Koninklijke Philips N.V., a Netherlands-based health technology company, received FDA approval for two advances in MR-only workflows such as (AI)-enabled MRCAT Head and Neck' and 'MacroMedics.' The (AI)-enabled MRCAT Head and Neck radiotherapy application facilitates the use of MR as the exclusive or primary imaging modality for planning radiotherapy, especially for soft tissue tumors located in the head and neck, as well as in the brain, pelvis, and prostate.

In March 2023, InvoX Pharma Ltd., a UK-based biopharmaceutical company, completed the acquisition of F-star Therapeutics Inc. for a sum of $161 million. This strategic move fortified InvoX Pharma's standing in the cancer therapeutics sector, expanding its portfolio and broadening its market reach. F-star Therapeutics Inc., based in the US, specializes in clinical-stage biopharmaceuticals, particularly focusing on head and neck cancer immunotherapy.

Major companies operating in the head and neck cancer therapeutics market include Pfizer Inc., F Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi Aventis LLC, Bristol-Myers-Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Incyte Corporation, Ono Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Hikma Pharmaceuticals PLC, Clinigen Group plc., Ligand Pharmaceuticals, Acceleron Pharma Inc., Taiho Pharmaceutical Co. Ltd., Boston Biomedical Inc., AB Science SA.

North America was the largest region in the head and neck cancer therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the head and neck cancer therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the head and neck cancer therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The head and neck cancer therapeutics market consists of sales of bleomycin sulfate, cetuximab, docetaxel, and erbitux. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Head And Neck Cancer Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on head and neck cancer therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for head and neck cancer therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The head and neck cancer therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Programmed Cell Death (PD) Inhibitors; Microtubule Inhibitors; Epidermal Growth Factor Receptor (EGFR) Inhibitors
• 2) By Route Of Administration: Injectable; Oral
• 3) By Distribution Channel: Retail And Specialty Pharmacies; Hospital Pharmacies; Online Pharmacies
• 4) By Application: Surgery; Radiation Therapy; Chemotherapy; Immunotherapy; Other Applications
• Subsegments:
• 1) By Programmed Cell Death (PD) Inhibitors: PD-1 Inhibitors; PD-L1 Inhibitors
• 2) By Microtubule Inhibitors: Taxanes; Vinca Alkaloids
• 3) By Epidermal Growth Factor Receptor (EGFR) Inhibitors: Monoclonal Antibodies; Tyrosine Kinase Inhibitors
• Companies Mentioned: Pfizer Inc.; F Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Head And Neck Cancer Therapeutics Market Characteristics

3. Head And Neck Cancer Therapeutics Market Trends And Strategies

4. Head And Neck Cancer Therapeutics Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Head And Neck Cancer Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Head And Neck Cancer Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Head And Neck Cancer Therapeutics Market Growth Rate Analysis
• 5.4. Global Head And Neck Cancer Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Head And Neck Cancer Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Head And Neck Cancer Therapeutics Total Addressable Market (TAM)

6. Head And Neck Cancer Therapeutics Market Segmentation

• 6.1. Global Head And Neck Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Programmed Cell Death (PD) Inhibitors
• Microtubule Inhibitors
• Epidermal Growth Factor Receptor (EGFR) Inhibitors
• 6.2. Global Head And Neck Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injectable
• Oral
• 6.3. Global Head And Neck Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Retail And Specialty Pharmacies
• Hospital Pharmacies
• Online Pharmacies
• 6.4. Global Head And Neck Cancer Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgery
• Radiation Therapy
• Chemotherapy
• Immunotherapy
• Other Applications
• 6.5. Global Head And Neck Cancer Therapeutics Market, Sub-Segmentation Of Programmed Cell Death (PD) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• PD-1 Inhibitors
• PD-L1 Inhibitors
• 6.6. Global Head And Neck Cancer Therapeutics Market, Sub-Segmentation Of Microtubule Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Taxanes
• Vinca Alkaloids
• 6.7. Global Head And Neck Cancer Therapeutics Market, Sub-Segmentation Of Epidermal Growth Factor Receptor (EGFR) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Tyrosine Kinase Inhibitors

7. Head And Neck Cancer Therapeutics Market Regional And Country Analysis

• 7.1. Global Head And Neck Cancer Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Head And Neck Cancer Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Head And Neck Cancer Therapeutics Market

• 8.1. Asia-Pacific Head And Neck Cancer Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Head And Neck Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Head And Neck Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Head And Neck Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Head And Neck Cancer Therapeutics Market

• 9.1. China Head And Neck Cancer Therapeutics Market Overview
• 9.2. China Head And Neck Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Head And Neck Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Head And Neck Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Head And Neck Cancer Therapeutics Market

• 10.1. India Head And Neck Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Head And Neck Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Head And Neck Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Head And Neck Cancer Therapeutics Market

• 11.1. Japan Head And Neck Cancer Therapeutics Market Overview
• 11.2. Japan Head And Neck Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Head And Neck Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Head And Neck Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Head And Neck Cancer Therapeutics Market

• 12.1. Australia Head And Neck Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Head And Neck Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Head And Neck Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Head And Neck Cancer Therapeutics Market

• 13.1. Indonesia Head And Neck Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Head And Neck Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Head And Neck Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Head And Neck Cancer Therapeutics Market

• 14.1. South Korea Head And Neck Cancer Therapeutics Market Overview
• 14.2. South Korea Head And Neck Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Head And Neck Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Head And Neck Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Head And Neck Cancer Therapeutics Market

• 15.1. Western Europe Head And Neck Cancer Therapeutics Market Overview
• 15.2. Western Europe Head And Neck Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Head And Neck Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Head And Neck Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Head And Neck Cancer Therapeutics Market

• 16.1. UK Head And Neck Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Head And Neck Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Head And Neck Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Head And Neck Cancer Therapeutics Market

• 17.1. Germany Head And Neck Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Head And Neck Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Head And Neck Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Head And Neck Cancer Therapeutics Market

• 18.1. France Head And Neck Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Head And Neck Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Head And Neck Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Head And Neck Cancer Therapeutics Market

• 19.1. Italy Head And Neck Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Head And Neck Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Head And Neck Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Head And Neck Cancer Therapeutics Market

• 20.1. Spain Head And Neck Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Head And Neck Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Head And Neck Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Head And Neck Cancer Therapeutics Market

• 21.1. Eastern Europe Head And Neck Cancer Therapeutics Market Overview
• 21.2. Eastern Europe Head And Neck Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Head And Neck Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Head And Neck Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Head And Neck Cancer Therapeutics Market

• 22.1. Russia Head And Neck Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Head And Neck Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Head And Neck Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Head And Neck Cancer Therapeutics Market

• 23.1. North America Head And Neck Cancer Therapeutics Market Overview
• 23.2. North America Head And Neck Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Head And Neck Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Head And Neck Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Head And Neck Cancer Therapeutics Market

• 24.1. USA Head And Neck Cancer Therapeutics Market Overview
• 24.2. USA Head And Neck Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Head And Neck Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Head And Neck Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Head And Neck Cancer Therapeutics Market

• 25.1. Canada Head And Neck Cancer Therapeutics Market Overview
• 25.2. Canada Head And Neck Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Head And Neck Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Head And Neck Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Head And Neck Cancer Therapeutics Market

• 26.1. South America Head And Neck Cancer Therapeutics Market Overview
• 26.2. South America Head And Neck Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Head And Neck Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Head And Neck Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Head And Neck Cancer Therapeutics Market

• 27.1. Brazil Head And Neck Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Head And Neck Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Head And Neck Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Head And Neck Cancer Therapeutics Market

• 28.1. Middle East Head And Neck Cancer Therapeutics Market Overview
• 28.2. Middle East Head And Neck Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Head And Neck Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Head And Neck Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Head And Neck Cancer Therapeutics Market

• 29.1. Africa Head And Neck Cancer Therapeutics Market Overview
• 29.2. Africa Head And Neck Cancer Therapeutics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Head And Neck Cancer Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Head And Neck Cancer Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Head And Neck Cancer Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Head And Neck Cancer Therapeutics Market Competitive Landscape
• 30.2. Head And Neck Cancer Therapeutics Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Head And Neck Cancer Therapeutics Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Sanofi Aventis LLC
• 31.3. Bristol-Myers-Squibb Company
• 31.4. AstraZeneca PLC
• 31.5. GlaxoSmithKline plc.
• 31.6. Takeda Pharmaceutical Company Limited
• 31.7. Eli Lilly and Company
• 31.8. Amgen Inc.
• 31.9. Boehringer Ingelheim International GmbH
• 31.10. Teva Pharmaceutical Industries Ltd.
• 31.11. Astellas Pharma Inc.
• 31.12. Daiichi Sankyo Company Limited
• 31.13. Eisai Co. Ltd.
• 31.14. Sun Pharmaceutical Industries Ltd.
• 31.15. Incyte Corporation

32. Global Head And Neck Cancer Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Head And Neck Cancer Therapeutics Market

34. Recent Developments In The Head And Neck Cancer Therapeutics Market

35. Head And Neck Cancer Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Head And Neck Cancer Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Head And Neck Cancer Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Head And Neck Cancer Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer